RECOVERY & TISSUE REPAIR / FAQ
Questions From the Research Record
Direct, citation-anchored answers to the questions most often brought to BPC-157, GLOW, and KLOW.
What does BPC-157 do in the body?
In animal models, BPC-157 has been linked to faster healing of gastric ulcers, transected tendons and blood vessels, most consistently through a pro-angiogenic mechanism — it up-regulates the VEGFR2 receptor and activates the downstream VEGFR2-Akt-eNOS signaling pathway that grows new blood vessels into damaged tissue [4]. It has also been shown to reduce gastric ulcer area and speed epithelial rebuilding in rats [5], and to accelerate Achilles-tendon healing across biomechanical and functional measures [6]. Human data are far more limited: a small intravenous safety pilot found BPC-157 well tolerated in two adults with no adverse effects on standard safety bloodwork, but that is a safety finding in two people, not a demonstrated effect [1].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and does not act as one. It is a synthetic 15-amino-acid peptide derived from a gastric-juice protein, and its research mechanisms are pro-angiogenic and cytoprotective rather than hormonal [4]. One reported route does involve sensitizing the growth-hormone receptor in tendon fibroblasts in laboratory models, which is a different thing from being a growth hormone itself — it means BPC-157 may make existing growth-hormone signaling more effective in that specific tissue context, not that BPC-157 supplies or replaces growth hormone.
Does BPC-157 work immediately?
The published animal literature does not support an immediate effect; healing outcomes in rat models were measured over days to weeks, not minutes or hours [5][6]. In research-use community reports — which are anecdotal, not clinical evidence — people commonly describe noticing changes in joint stiffness or pain over one to three weeks, not immediately. BPC-157 also clears the body quickly: its elimination half-life is under 30 minutes in formal pharmacokinetic testing [3], which argues against any lasting immediate effect from a single dose and is consistent with why it is studied on a repeated schedule in animal models, not as a one-time intervention.
Does BPC-157 damage the liver?
The available evidence does not show liver damage from BPC-157. In the one intravenous safety pilot conducted in humans, up to 20 mg given to two healthy adults produced no measurable changes in hepatic (liver) biomarkers, alongside no changes in cardiac, renal, thyroid or glucose markers [1]. That said, this is a two-person pilot, not a large safety study, and a 2025 review is explicit that rigorous, large-scale human trials of BPC-157 are lacking [2]. The honest answer is that no liver-damage signal has been reported, but the human safety dataset is too small to rule the possibility out with confidence.
What is GLOW peptide?
GLOW is not a single molecule but a co-formulated combination of three separate research peptides — most commonly GHK-Cu, BPC-157, and TB-500 — sold together in one research vial around a skin-renewal and tissue-repair rationale. A commonly cited research-label ratio is 10 mg BPC-157, 10 mg TB-500 and 50 mg GHK-Cu. No FDA-approved combination product with this composition exists, and no controlled study has tested the three-peptide blend itself, only its individual components [8].
What does the GLOW peptide do?
GLOW's rationale rests on three separate, individually studied mechanisms working together: GHK-Cu stimulates collagen, elastin and other matrix proteins in skin [9][10]; BPC-157 promotes new blood-vessel growth through the VEGFR2-Akt-eNOS pathway [4]; and TB-500 is associated with cell migration into damaged tissue. In research-use communities — reports that are anecdotal, not clinical evidence — people most often describe a brighter, more even skin tone and faster-looking wound healing. No study has tested the blend itself, so what GLOW does as a combination has not been directly measured.
What does GLOW peptide have in it?
The most commonly listed GLOW composition is three peptides: GHK-Cu (a copper-binding tripeptide, roughly 402.9 Da), BPC-157 (a 15-amino-acid pentadecapeptide, roughly 1,419 Da), and TB-500 (the acetylated heptapeptide Ac-LKKTETQ, a fragment of thymosin beta-4). A commonly cited research-label ratio is 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 per vial, though exact ratios vary by formulation and are not standardized.
What peptides are in the GLOW blend?
GHK-Cu, BPC-157, and TB-500 are the three peptides most commonly listed in the GLOW blend. Each is chemically and pharmacologically distinct: GHK-Cu is a copper(II)-tripeptide complex tied to matrix and collagen research [9][10]; BPC-157 is a pentadecapeptide tied to angiogenesis and tissue protection [4]; and TB-500 is a synthetic fragment of thymosin beta-4 tied to cell migration. They are co-dissolved in a single vial rather than chemically bonded together.
What is KLOW peptide?
KLOW is a four-peptide research blend that extends the GLOW formula (GHK-Cu, BPC-157, TB-500) by adding KPV, a small anti-inflammatory tripeptide. The most widely listed research-vial composition is an 80 mg total vial: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. As with GLOW, no FDA-approved combination exists, and no controlled study has tested the four-peptide blend itself [8].
What is KLOW peptide used for?
KLOW is studied, at the individual-component level, for tissue and skin repair (GHK-Cu [9][10] and BPC-157 [4]), cell migration into damaged tissue (TB-500), and suppression of inflammatory signaling (KPV, via the NF-kB and MAP-kinase pathways) [12]. Community reports — anecdotal, not clinical evidence — describe it being used for tendon and joint recovery alongside a broader "less inflamed" feeling credited to the KPV arm. No study has evaluated the four-peptide combination as a single intervention.
Where do you inject KLOW peptide?
This desk does not provide injection guidance, dosing instructions, or administration advice for any peptide, including KLOW. Community reports describe subcutaneous administration as the most commonly discussed route for peptides of this kind, but that is a description of what is reported in unregulated, unverified contexts, not a recommendation. KLOW is not an approved medicine, and administration decisions require a licensed clinician — which is not what this page is.
How much KLOW peptide per day?
This page states no dose. KLOW is not an FDA-approved product, no controlled study has tested the four-peptide combination in any dosing regimen, and this desk does not recommend an amount, frequency, or schedule for any person. Community-sourced ratios describing an 80 mg total vial (50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg KPV) describe how the product is commonly formulated for research sale, not a validated per-day amount for use in a person.